Ophthalmology · Warner Robins, GA
NPI
1306867387
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
216 Corder Rd
Warner Robins, GA, 31088
Phone (478) 923-5872
Groups this clinician bills Medicare through
Medicare paid, 2024
$224K
5,283 services
Medicare patients, 2024
1,193
Average age 76
Drug cost, 2024
$1.4M
7,168 prescriptions
Company payments, 2025
$533
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael B Minix was code 99213 (office e&m - established), 1,065 times for 792 patients. In total Michael B Minix billed 5,283 services in 23 codes, and Medicare paid $224K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-06-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,065 | 792 | $58.35 | $62K |
| 92250 Angiography | Office | 991 | 874 | $22.87 | $23K |
| 92133 Computerized Ophthalmic Imaging | Office | 752 | 749 | $22.67 | $17K |
| 83861 Clinical Chemistry | Office | 702 | 339 | $21.97 | $15K |
| 92014 Ophthalmological E&M | Office | 630 | 629 | $75.11 | $47K |
| 92083 Vision, Hearing, and Speech Services | Office | 593 | 593 | $38.52 | $23K |
| 99214 Office E&M - Established | Office | 315 | 266 | $82.52 | $26K |
| 65205 Eye | Office | 67 | 63 | $16.16 | $1,083 |
| 67820 Eye | Office | 40 | 35 | $12.16 | $486 |
| 99204 Office E&M - New | Office | 30 | 30 | $97.81 | $2,934 |
| 92012 Ophthalmological E&M | Office | 27 | 27 | $54.31 | $1,466 |
| 99203 Office E&M - New | Office | 27 | 27 | $62.91 | $1,698 |
| 92004 Ophthalmological E&M | Office | 26 | 26 | $92.91 | $2,416 |
By year: 2022 $259K for 5,920 services; 2023 $266K for 5,992 services; 2024 $224K for 5,283 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83861 Clinical Chemistry | 702 | 339 | $21.97 | $15K |
Medicare prescription drug claims, 2024
In 2024, the drug Michael B Minix prescribed most often to Medicare patients was Latanoprost, with 1,638 prescriptions and refills. In total Michael B Minix wrote 7,168 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Latanoprost Generic | 1,638 | 3,380 | 457 | $18K |
| Dorzolamide Hcl Generic | 1,054 | 2,205 | 283 | $20K |
| Brimonidine Tartrate Generic | 902 | 1,673 | 264 | $33K |
| Lumigan Bimatoprost | 723 | 1,292 | 184 | $334K |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 334 | 651 | 91 | $4,332 |
| Timolol Maleate Generic | 286 | 617 | 97 | $3,758 |
| Erythromycin Erythromycin Base | 256 | 267 | 121 | $2,971 |
| Restasis Cyclosporine | 254 | 529 | 101 | $323K |
| Rhopressa Netarsudil Mesylate | 243 | 405 | 69 | $127K |
| Travoprost Generic | 132 | 229 | 34 | $16K |
| Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol | 132 | 231 | 36 | $22K |
| Alphagan P Brimonidine Tartrate | 131 | 207 | 29 | $55K |
| Combigan Brimonidine Tartrate/Timolol | 111 | 170 | 29 | $38K |
| Vyzulta Latanoprostene Bunod | 87 | 145 | 21 | $44K |
| Simbrinza Brinzolamide/Brimonidine Tart | 85 | 139 | 23 | $28K |
Brand drugs: 2,554 claims; generic drugs: 4,614 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael B Minix $533 ($533 in general payments such as food, travel and fees) from 6 companies. The largest payer was Harrow Eye, LLC with $162.
| Company | Payments | Amount |
|---|---|---|
| Harrow Eye, LLC | 5 | $162 |
| Tarsus Pharmaceuticals, Inc. TARS | 11 | $144 |
| Abbvie Inc. ABBV | 6 | $138 |
| Alcon Vision LLC ALC | 2 | $41.84 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 1 | $27.04 |
| Amgen Inc. AMGN | 1 | $20.43 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.